PD-L1 Overexpression, SWI/SNF Complex Deregulation, and Profound Transcriptomic Changes Characterize Cancer-Dependent Exhaustion of Persistently Activated CD4
CD4+ effector T cells
PD-1
PD-L1
PD-L1/PD-1 axis
SWI/SNF complex
T cell exhaustion
Journal
Cancers
ISSN: 2072-6694
Titre abrégé: Cancers (Basel)
Pays: Switzerland
ID NLM: 101526829
Informations de publication
Date de publication:
18 Aug 2021
18 Aug 2021
Historique:
received:
29
06
2021
revised:
04
08
2021
accepted:
13
08
2021
entrez:
27
8
2021
pubmed:
28
8
2021
medline:
28
8
2021
Statut:
epublish
Résumé
Growing tumors avoid recognition and destruction by the immune system. During continuous stimulation of tumor-infiltrating lymphocytes (TILs) by tumors, TILs become functionally exhausted; thus, they become unable to kill tumor cells and to produce certain cytokines and lose their ability to proliferate. This collectively results in the immune escape of cancer cells. Here, we show that breast cancer cells expressing PD-L1 can accelerate exhaustion of persistently activated human effector CD4
Identifiants
pubmed: 34439305
pii: cancers13164148
doi: 10.3390/cancers13164148
pmc: PMC8391521
pii:
doi:
Types de publication
Journal Article
Langues
eng
Subventions
Organisme : Polpharma Scientific Foundation
ID : 5/XVII/18
Organisme : National Science Center Poland (NCN)
ID : 2016/23/N/NZ1/01138
Organisme : National Science Center Poland (NCN)
ID : UMO-2014/15/B/NZ5/03532
Organisme : Maria Sklodowska-Curie National Research Institute of Oncology internal grant
ID : GW017
Organisme : Diamond grant by Ministry of Science and Higher Education (Poland)
ID : 0070/DIA/2015/44
Références
Nat Rev Drug Discov. 2020 Mar;19(3):185-199
pubmed: 31900462
Oncotarget. 2018 Jan 16;9(9):8597-8613
pubmed: 29492220
Trends Pharmacol Sci. 2019 Sep;40(9):613-623
pubmed: 31331639
Genome Biol. 2014;15(12):550
pubmed: 25516281
Blood. 2007 Jun 15;109(12):5346-54
pubmed: 17327412
J Immunother Cancer. 2018 Jun 18;6(1):57
pubmed: 29914571
J Hematol Oncol. 2018 Aug 2;11(1):100
pubmed: 30068361
Hum Vaccin Immunother. 2020 Oct 2;16(10):2312-2317
pubmed: 31860375
J Exp Med. 2002 Aug 19;196(4):459-68
pubmed: 12186838
Nature. 2017 Apr 13;544(7649):250-254
pubmed: 28371798
Oncoimmunology. 2020 Apr 14;9(1):1747349
pubmed: 32363117
Biomed Res Int. 2021 Feb 25;2021:6616391
pubmed: 33728333
Front Immunol. 2020 Dec 14;11:594609
pubmed: 33381115
Front Immunol. 2020 Nov 30;11:586907
pubmed: 33329566
Front Cell Dev Biol. 2020 Feb 11;8:17
pubmed: 32117960
Cancer Treat Rev. 2017 Jan;52:71-81
pubmed: 27951441
Semin Immunol. 2014 Feb;26(1):38-47
pubmed: 24602448
Bioinformatics. 2015 Jan 15;31(2):166-9
pubmed: 25260700
Int J Mol Sci. 2020 Oct 05;21(19):
pubmed: 33027962
Science. 2011 Mar 25;331(6024):1565-70
pubmed: 21436444
Nat Immunol. 2011 Jun;12(6):492-9
pubmed: 21739672
Eur J Immunol. 2016 Jul;46(7):1574-82
pubmed: 27271222
J Clin Invest. 2018 May 1;128(5):2104-2115
pubmed: 29664018
Cancer Gene Ther. 2021 Feb 18;:
pubmed: 33603130
Biostat Bioinforma Biomath. 2013 Aug;3(3):71-85
pubmed: 25558171
Transl Cancer Res. 2017 Mar;6(Suppl 2):S384-S387
pubmed: 29188192
Front Oncol. 2018 Aug 03;8:237
pubmed: 30123774
Nat Immunol. 2021 Feb;22(2):205-215
pubmed: 33398183
Brief Funct Genomics. 2019 Mar 22;18(2):99-106
pubmed: 29554204
Biomed Res Int. 2020 Oct 23;2020:8765028
pubmed: 33150182
Nat Rev Immunol. 2015 Aug;15(8):486-99
pubmed: 26205583
Sci Rep. 2019 Aug 21;9(1):12150
pubmed: 31434983
Nature. 2016 Sep 22;537(7621):539-543
pubmed: 27626381
J Exp Med. 2010 Oct 25;207(11):2469-77
pubmed: 20921286
Proc Natl Acad Sci U S A. 2019 Jan 22;116(4):1361-1369
pubmed: 30545915
Nat Methods. 2009 May;6(5):359-62
pubmed: 19377485
Nat Rev Immunol. 2019 Nov;19(11):665-674
pubmed: 31570879